Molina Healthcare, Inc.: Q3 FY2025 earnings call

What management said about Q3 FY2025, from the documents filed with the SEC on 22 October 2025: press release. Guidance figures: 8 raised, 11 lowered, 4 new, 1 kept. The quarter’s numbers.

Read the filing

Key takeaways

• Premium revenue up, adjusted earnings down: Premium revenue was about $10.8 billion, up 12%, on acquisitions, rate increases and footprint growth. Adjusted EPS of $1.84 fell 69%, and GAAP EPS of $1.51 fell 73%. Source
• Medicaid offset Medicare and Marketplace losses: Medicaid added $3.52 per diluted share to adjusted earnings. Medicare and Marketplace together reduced results by $1.68 per diluted share. Source
• Marketplace MCR reached 95.6%: Marketplace premium revenue was $1,197 million against $659 million. MCR was 95.6% versus 73.0%, and medical margin fell to $53 million from $179 million. Source
• Adjusted EPS guidance cut to about $14.00: Full-year adjusted EPS guidance is about $14.00, down from no less than $19.00. GAAP EPS guidance is about $11.90, down from no less than $16.90. Source
• Medical cost trend drove the guidance cut: Management cited higher medical cost trend in all segments, and disproportionately in Marketplace. Operating leverage, a lower tax rate and buybacks partly offset it. Source
• Operating cash flow turned negative: Operating cash flow for nine months was an outflow of $237 million, against an inflow of $868 million a year earlier. Source
• Preliminary 2026 adjusted EPS near 2025: Management expects to provide formal 2026 guidance with fourth-quarter results. Preliminary 2026 adjusted EPS is expected to approximate full-year 2025 guidance. Source

“Our Medicaid business continues to perform well in a challenging medical cost trend environment”

Joseph Zubretsky, President and Chief Executive Officer

Guidance

What changed from last quarter

• Guidance raised: Full-year premium revenue guidance raised to about $42.5 billion from about $42 billion. Source
• Guidance lowered: Full-year adjusted EPS guidance lowered to about $14.00 from no less than $19.00. Source
• Guidance lowered: Full-year GAAP EPS guidance lowered to about $11.90 from no less than $16.90. Source
• New guidance: Implied fourth-quarter 2025 adjusted EPS of about $0.35 per diluted share was provided. Source
• New guidance: A preliminary 2026 adjusted EPS view was provided, expected to approximate full-year 2025 guidance. Source
• New: The initial 2026 view includes reduced exposure to Marketplace. Source
• Guidance kept: New store embedded earnings held at $8.65 per diluted share. Source

Results and growth drivers

• Premium revenue up, adjusted earnings down: Premium revenue was about $10.8 billion, up 12%, on acquisitions, rate increases and footprint growth. Adjusted EPS of $1.84 fell 69%, and GAAP EPS of $1.51 fell 73%. Source
• Adjusted earnings fell 69% year over year: Adjusted net income was $1.84 per diluted share, versus $6.01 a year earlier. GAAP net income was $79 million against $326 million. Source
• Medicaid offset Medicare and Marketplace losses: Medicaid added $3.52 per diluted share to adjusted earnings. Medicare and Marketplace together reduced results by $1.68 per diluted share. Source
• Membership grew 30,000 year over year: About 5.6 million members at September 30, 2025, up 30,000 from a year earlier. Marketplace membership reached 713,000, up from 403,000 at December 31, 2024. Source

Segments: Medicaid, Medicare, Marketplace

• Medicaid MCR rose to 92.0%: Medicaid premium revenue was $8,015 million against $7,668 million. MCR was 92.0% versus 90.5%, and medical margin was $639 million against $730 million. Source
• Medicare MCR rose to 93.6%: Medicare premium revenue was $1,610 million, up from $1,367 million. MCR was 93.6% against 89.6%, and medical margin was $103 million against $142 million. Source
• Marketplace MCR reached 95.6%: Marketplace premium revenue was $1,197 million against $659 million. MCR was 95.6% versus 73.0%, and medical margin fell to $53 million from $179 million. Source

“The headline for the quarter is that approximately half of our underperformance is driven by the Marketplace business”

Joseph Zubretsky, President and Chief Executive Officer

Medical costs and utilization

• Consolidated MCR rose to 92.6%: The consolidated MCR was 92.6% against 89.2% a year earlier. The nine-month MCR was 90.8% against 88.8%. Source
• Medicaid cost pressure partly offset: Medicaid faced medical cost pressure from continued high utilization, partly offset by rate updates that took effect in the quarter. Source
• Medicare utilization among high-acuity members: The Medicare MCR of 93.6% reflected higher utilization among high-acuity members, particularly long-term services and supports and pharmacy. Source
• Marketplace utilization ran above risk revenue: Management said Marketplace utilization continued to run much higher relative to risk adjustment revenue, producing the 95.6% MCR. Source
• Days in claims payable at 46: Days in claims payable was 46 at September 30, 2025, against 48 a year earlier in the nine-month table. Source
• Prior-year claims amounts lower: Prior-year amounts were $(124) million for the nine months of 2025, against $(625) million in 2024, within total medical care costs of $29,352 million. Source

Full-year 2025 guidance revised

• Premium revenue guidance raised to $42.5B: Full-year premium revenue guidance is about $42.5 billion, up roughly 10% from 2024, compared with about $42 billion before. Source
• Adjusted EPS guidance cut to about $14.00: Full-year adjusted EPS guidance is about $14.00, down from no less than $19.00. GAAP EPS guidance is about $11.90, down from no less than $16.90. Source
• Medical cost trend drove the guidance cut: Management cited higher medical cost trend in all segments, and disproportionately in Marketplace. Operating leverage, a lower tax rate and buybacks partly offset it. Source
• Fourth quarter implied at $0.35: Implied fourth-quarter 2025 adjusted EPS is about $0.35 per diluted share, following the revised full-year guidance. Source
• Fourth-quarter Medicaid gain and offset: Management expects Medicaid to add about $3.00 per diluted share in the fourth quarter, offset by about $2.65 of losses in Medicare and Marketplace. Source
• Total revenue and net income guidance set: Full-year guidance also sets total revenue at $44.5 billion, GAAP net income at $630 million and adjusted net income at $742 million. Source

“We continue to grow, we believe the margin challenges will not persist, and we are encouraged by the margin improvement potential in 2026.”

Joseph Zubretsky, President and Chief Executive Officer

Costs, margins and operating income

• G&A ratio held at 6.4%: The G&A ratio was 6.4% and the adjusted G&A ratio 6.3%, which management attributed to continued operating discipline. G&A expense was $729 million. Source
• Operating income fell to $137 million: Operating income was $137 million, against $467 million a year earlier. Nine-month operating income was $943 million against $1,327 million. Source
• Adjusted after-tax margin fell: Adjusted after-tax margin was 0.8% for the quarter, against 3.4% a year earlier, and 2.1% for nine months against 3.4%. Source

Cash, balance sheet and capital

• Operating cash flow turned negative: Operating cash flow for nine months was an outflow of $237 million, against an inflow of $868 million a year earlier. Source
• Settlements and timing drove cash decline: Management attributed the cash decline to Medicaid risk corridor and Marketplace risk transfer settlements, plus timing of government receivables and payables. Source
• Parent company cash fell to $108 million: Parent company cash and investments were $108 million at September 30, 2025, against $445 million at December 31, 2024. Source
• Buybacks rose, borrowing funded part: Nine-month common stock purchases were $1,000 million, against $500 million. Borrowings were $1,100 million, and long-term debt rose to $3,664 million. Source

Strategy, acquisitions and 2026 expectation

• Preliminary 2026 adjusted EPS near 2025: Management expects to provide formal 2026 guidance with fourth-quarter results. Preliminary 2026 adjusted EPS is expected to approximate full-year 2025 guidance. Source
• Marketplace exposure reduced for 2026: The initial 2026 view includes reduced Marketplace exposure, with segment earnings at least break even. Source
• New store embedded earnings held at $8.65: New store embedded earnings remain at $8.65 per diluted share. The measure covers expected 2026 to 2028 EPS impact from new Medicaid and Medicare contracts and acquisitions. Source
• Acquisition costs estimated at $46M: Non-recurring costs tied to recently announced acquisitions are estimated at about $46 million. Source

Coming up, as management said on 22 October 2025

• Embedded earnings expected 2026 to 2028: New store embedded earnings are expected to be achieved between 2026 and 2028 from new contracts and recent acquisitions. Source
• Acquisition costs of about $46M: Non-recurring costs tied to the recently announced acquisitions are estimated at about $46 million. Source

Figures management reported

Risks management discussed

• Operational: Higher medical cost trend in all segments, with Marketplace trend expected to continue through year-end, is cited as the driver of the guidance cut. Source
• Operational: Marketplace utilization ran much higher than risk adjustment revenue, producing a 95.6% MCR in the quarter. Source
• Financial: Operating cash flow was an outflow of $237 million for nine months, and parent company cash fell to $108 million. Source
• Regulatory: Medicaid risk corridor and Marketplace risk transfer settlement activity contributed to lower operating cash flow in the period. Source

Earlier plans management reported on

• Not stated: Management says the new store embedded earnings figure remains at $8.65 per diluted share. Source
• Not stated: Management said it believes the margin challenges will not persist. Source

Other quarters

• Q2 FY2026 earnings call
• Q1 FY2026 earnings call
• Q4 FY2025 earnings call
• Q2 FY2025 results

Summarised with AI from the documents the company filed with the SEC. Every point is checked against the filing before it is shown: management’s own words word for word, figures against the line or table row they come from. A point that fails the check is left out. Source opens the filing at that line.